Trial · NCT01346293
Results by group154
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 154
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Booster Response to the Pertussis Antigens Following Vaccination With Either DTaP-IPV or DAPTACEL® + IPOL® Vaccine | DTaP-IPV | Anti-Pertussis toxoid (N=252, 247) | 240 | Participants | |
| Number of Participants With Booster Response to the Pertussis Antigens Following Vaccination With Either DTaP-IPV or DAPTACEL® + IPOL® Vaccine | DAPTACEL®+IPOL® | Anti-Pertussis toxoid (N=252, 247) | 222 | Participants | |
| Number of Participants With Booster Response to the Pertussis Antigens Following Vaccination With Either DTaP-IPV or DAPTACEL® + IPOL® Vaccine | DTaP-IPV | Anti-Filamentous hemagglutinin (N=255, 248) | 242 | Participants | |
| Number of Participants With Booster Response to the Pertussis Antigens Following Vaccination With Either DTaP-IPV or DAPTACEL® + IPOL® Vaccine | DAPTACEL®+IPOL® | Anti-Filamentous hemagglutinin (N=255, 248) | 217 | Participants | |
| Number of Participants With Booster Response to the Pertussis Antigens Following Vaccination With Either DTaP-IPV or DAPTACEL® + IPOL® Vaccine | DTaP-IPV | Anti-Pertactin (N=254, 248) | 246 | Participants | |
| Number of Participants With Booster Response to the Pertussis Antigens Following Vaccination With Either DTaP-IPV or DAPTACEL® + IPOL® Vaccine | DAPTACEL®+IPOL® | Anti-Pertactin (N=254, 248) | 231 | Participants | |
| Number of Participants With Booster Response to the Pertussis Antigens Following Vaccination With Either DTaP-IPV or DAPTACEL® + IPOL® Vaccine | DTaP-IPV | Anti-Fimbriae types 2 and 3 (N=250, 249) | 243 | Participants | |
| Number of Participants With Booster Response to the Pertussis Antigens Following Vaccination With Either DTaP-IPV or DAPTACEL® + IPOL® Vaccine | DAPTACEL®+IPOL® | Anti-Fimbriae types 2 and 3 (N=250, 249) | 230 | Participants | |
| Geometric Mean Concentrations of the Pertussis Antibodies Before and Following Vaccination With Either DTaP-IPV or DAPTACEL® + IPOL® Vaccine | DTaP-IPV | Anti-PT pre-vaccination (N=254, 248) | 5.16 | 95% Confidence Interval 4.48 to 5.94 | Titers |
| Geometric Mean Concentrations of the Pertussis Antibodies Before and Following Vaccination With Either DTaP-IPV or DAPTACEL® + IPOL® Vaccine | DAPTACEL®+IPOL® | Anti-PT pre-vaccination (N=254, 248) | 4.74 | 95% Confidence Interval 4.18 to 5.39 | Titers |
| Geometric Mean Concentrations of the Pertussis Antibodies Before and Following Vaccination With Either DTaP-IPV or DAPTACEL® + IPOL® Vaccine | DTaP-IPV | Anti-PT post-vaccination (N=261, 252) | 121 | 95% Confidence Interval 108 to 134 | Titers |
| Geometric Mean Concentrations of the Pertussis Antibodies Before and Following Vaccination With Either DTaP-IPV or DAPTACEL® + IPOL® Vaccine | DAPTACEL®+IPOL® | Anti-PT post-vaccination (N=261, 252) | 61.3 | 95% Confidence Interval 54.5 to 68.9 | Titers |
| Geometric Mean Concentrations of the Pertussis Antibodies Before and Following Vaccination With Either DTaP-IPV or DAPTACEL® + IPOL® Vaccine | DTaP-IPV | Anti-FHA pre-vaccination (N=255, 248) | 7.93 | 95% Confidence Interval 6.63 to 9.47 | Titers |
| Geometric Mean Concentrations of the Pertussis Antibodies Before and Following Vaccination With Either DTaP-IPV or DAPTACEL® + IPOL® Vaccine | DAPTACEL®+IPOL® | Anti-FHA pre-vaccination (N=255, 248) | 9.42 | 95% Confidence Interval 7.85 to 11.3 | Titers |
| Geometric Mean Concentrations of the Pertussis Antibodies Before and Following Vaccination With Either DTaP-IPV or DAPTACEL® + IPOL® Vaccine | DTaP-IPV | Anti-FHA post-vaccination (N=263, 253) | 123 | 95% Confidence Interval 108 to 141 | Titers |
| Geometric Mean Concentrations of the Pertussis Antibodies Before and Following Vaccination With Either DTaP-IPV or DAPTACEL® + IPOL® Vaccine | DAPTACEL®+IPOL® | Anti-FHA post-vaccination (N=263, 253) | 79.0 | 95% Confidence Interval 69.3 to 90.0 | Titers |
| Geometric Mean Concentrations of the Pertussis Antibodies Before and Following Vaccination With Either DTaP-IPV or DAPTACEL® + IPOL® Vaccine | DTaP-IPV | Anti-PRN pre-vaccination (N=255, 249) | 18.6 | 95% Confidence Interval 16.2 to 21.3 | Titers |
| Geometric Mean Concentrations of the Pertussis Antibodies Before and Following Vaccination With Either DTaP-IPV or DAPTACEL® + IPOL® Vaccine | DAPTACEL®+IPOL® | Anti-PRN pre-vaccination (N=255, 249) | 16.7 | 95% Confidence Interval 14.6 to 19.1 | Titers |
| Geometric Mean Concentrations of the Pertussis Antibodies Before and Following Vaccination With Either DTaP-IPV or DAPTACEL® + IPOL® Vaccine | DTaP-IPV | Anti-PRN post-vaccination (N=262, 252) | 283 | 95% Confidence Interval 252 to 317 | Titers |
| Geometric Mean Concentrations of the Pertussis Antibodies Before and Following Vaccination With Either DTaP-IPV or DAPTACEL® + IPOL® Vaccine | DAPTACEL®+IPOL® | Anti-PRN post-vaccination (N=262, 252) | 187 | 95% Confidence Interval 164 to 214 | Titers |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01346293/results